Citations

Clear

634 citation(s) found for "Hall, A".

Delayed Patch-Test Reading After 5 Days: An Update From the Mayo Clinic Contact Dermatitis Group
Chaudhry, Hafsa, Drage, Lisa A., Hall, Matthew R., Killian, Jill M. , Prakash, Amy V., Yiannias, James A. , Davis, Mark D.P. , Cantwell, Hafsa M. , Chaudhry, Hafsa M, el‐Azhary, Rokea A.

Mayo Clinic

Dermatitis® | July 18, 2017 | Volume: 28 | Issue: 4 | Pages: 253-260

10.1097/der.0000000000000297 | PMID 28719473 Get It

Background Patch-test readings after day 5 have previously been used to identify delayed reactions to metals and topical antibiotics. Objective The aims of this study were to identify allergens for which late readings (beyond day 5) would be most valuable and to compare our results with our previous study on delayed patch-test readings. Methods This was a retrospective study of 298 patients who underwent metal and corticosteroid series patch testing from January 1, 2007, through December 31, 2013. Patch-test readings were conducted on days 3 and 5 and at least once sometime between days 7 and 14. All reactions were examined at each reading. Conclusions These results were concordant with our previous findings that additional readings after day 7 are particularly useful for identifying reactions to metals (gold, cobalt, beryllium, palladium), specific preservatives (dodecyl gallate, propolis), and the topical antibiotic neomycin. New delayed reactions to bacitracin, p -phenylenediamine, and topical corticosteroids were not seen in this cohort.
Gene–environment interactions involving functional variants: Results from the Breast Cancer Association Consortium
Barrdahl, Myrto , Hopper, John L. , Southey, Melissa C. , Fasching, Peter A. , Beckmann, Matthias W. , Gago-Domínguez, Manuela , Castelao, Jose E. , Guénel, Pascal , Truong, Thérèse , Bojesen, Stig E. , Gapstur, Susan M. , Gaudet, Mia M. , Brenner, Hermann , Brauch, Hiltrud , Hamann, Ute , Mannermaa, Arto, Lambrechts, Diether , Jongen, Lynn , Flesch‐Janys, Dieter, Thoene, Kathrin, Couch, Fergus J. , Simard, Jacques , Goldberg, Mark S. , Figueroa, Jonine D. , Michailidou, Kyriaki , Bolla, Manjeet K. , Wang, Qin , Eilber, Ursula, Swerdlow, Anthony J. , Schoemaker, Minouk J. , García‐Closas, Montserrat , Easton, Douglas F. , Chang‐Claude, Jenny , Durocher, Francine , Barrdahl, Myrto , Lambrechts, Diether , Rudolph, Anja , Fasching, Peter A , Barrdahl, Myrto , Rudolph, Anja , Broeks, Annegien , Arndt, Volker , Mannermaa, Arto, Couch, Fergus J. , Giles, Graham G. , Dennis, Joe , Behrens, Sabine , Czene, Kamila , Hall, Per N , Cox, Angela , Cross, Simon S. , Dunning, Alison M. , Kaaks, Rudolf , Pharoah, Paul D.P. , Schmidt, Marjanka K. , Milne, Roger L. , Lambrechts, Diether , Swerdlow, Anthony J , Southey, Melissa C , Lambrechts, Diether , Brenner, Hermann , Gago-Dominguez, Manuela , Guénel, Pascal , García-Closas, Montserrat , Michailidou, Kyriaki , Simard, Jacques , Figueroa, Jonine D , Bojesen, Stig E , Schoemaker, Minouk J , Truong, Therese , Brauch, Hiltrud

Mayo Clinic

International Journal of Cancer | July 3, 2017 | Volume: 141 | Issue: 9 | Pages: 1830-1840

10.1002/ijc.30859 | PMID 28670784 Get It

Investigating the most likely causal variants identified by fine‐mapping analyses may improve the power to detect gene–environment interactions. We assessed the interplay between 70 single nucleotide polymorphisms identified by genetic fine‐scale mapping of susceptibility loci and 11 epidemiological breast cancer risk factors in relation to breast cancer. Analyses were conducted on up to 58,573 subjects (26,968 cases and 31,605 controls) from the Breast Cancer Association Consortium, in one of the largest studies of its kind. Analyses were carried out separately for estrogen receptor (ER) positive (ER+) and ER negative (ER–) disease. The Bayesian False Discovery Probability (BFDP) was computed to assess the noteworthiness of the results. Four potential gene–environment interactions were identified as noteworthy (BFDP < 0.80) when assuming a true prior interaction probability of 0.01. The strongest interaction result in relation to overall breast cancer risk was found between CFLAR‐rs7558475 and current smoking (ORint = 0.77, 95% CI: 0.67–0.88, pint = 1.8 × 10−4). The interaction with the strongest statistical evidence was found between 5q14‐rs7707921 and alcohol consumption (ORint =1.36, 95% CI: 1.16–1.59, pint = 1.9 × 10−5) in relation to ER– disease risk. The remaining two gene–environment interactions were also identified in relation to ER– breast cancer risk and were found between 3p21‐rs6796502 and age at menarche (ORint = 1.26, 95% CI: 1.12–1.43, pint =1.8 × 10−4) and between 8q23‐rs13267382 and age at first full‐term pregnancy (ORint = 0.89, 95% CI: 0.83–0.95, pint = 5.2 × 10−4). While these results do not suggest any strong gene–environment interactions, our results may still be useful to inform experimental studies. These may in turn, shed light on the potential interactions observed.
Primary Realignment of Posterior Urethral Injuries
Patterson, David E., Barrett, David M. , Myers, Robert P., DeWeerd, James H., Hall, Brad B., Benson, Ralph C.

Mayo Clinic

Journal of Urology | June 30, 2017 | Volume: 129 | Issue: 3 | Pages: 513-515

10.1016/s0022-5347(17)52209-0 | PMID 6834534 Get It

Body mass index and breast cancer survival: a Mendelian randomization analysis
Guo, Qi , Burgess, Stephen , Bolla, Manjeet K. , Wang, Qin , Abraham, Jean , Aittomäki, Kristiina, Andrulis, Irene L. , Apicella, Carmel, Berg, Christine D. , Blomqvist, Carl , Bojesen, Stig E. , Brand, Judith S. , Brenner, Hermann , Burwinkel, Barbara , Caldas, Carlos , Campa, Daniele , Canzian, Federico , Chang‐Claude, Jenny , Couch, Fergus J. , Darabi, Hatef, Diver, W. Ryan , Earl, Helena , Eccles, Diana M, Ekici, Arif B. , Eriksson, Mikael , Evans, D. Gareth , Fasching, Peter A. , Figueroa, Jonine D. , Flesch‐Janys, Dieter, Flyger, Henrik, Gapstur, Susan M. , Gaudet, Mia M. , Glendon, Gord, Grip, Mervi, Haeberle, Lothar, Haiman, Christopher A., Hamann, Ute, Hankinson, Susan E. , Hein, Alexander , Hiller, Louise , Hogervorst, Frans B.L., Holleczek, Bernd , Hooning, Maartje J. , Hoover, Robert N. , Humphreys, Keith , Hunter, David J., Hüsing, Anika , Jakubowska, Anna , Jukkola‐Vuorinen, Arja , Kabisch, Maria, Investigators, kConFab/AOCS, Knight, Julia A. , Koppert, Linetta B. , Kosma, Veli‐Matti , Kristensen, Vessela N. , Lambrechts, Diether , Li, Jingmei , Lindblom, Annika , Lindström, Sara, Lissowska, Jolanta , Lubiński, Jan , Machiela, Mitchell J. , Mannermaa, Arto, Manoukian, Siranoush , Margolin, Sara , Marmé, F., McLean, Catriona , Menéndez, Primitiva, Mulligan, Anna Marie , Muranen, Taru , Neven, Patrick , Nielsen, Sune F. , Nordestgaard, Børge G. , Perez, Jose IA, Peterlongo, Paolo , Phillips, Kelly‐Anne , Poole, Christopher, Pylkäs, Katri , Radice, Paolo , Rüdiger, Thomas , Sawyer, Elinor J. , Schumacher, Fredrick R. , Seynaeve, Caroline, Shah, Mitul , Smeets, Ann , Southey, Melissa C. , Tollenaar, Rob A.�E.�M. , Tomlinson, Ian , Ulmer, Hans-Ulrich, Vachon, Celine M. , Ouweland, Ans MW van den, Veer, Laura J. van’t , Wildiers, Hans , Winqvist, Robert , Zamora, M. Pilar , Chenevix‐Trench, Georgia , Dörk, Thilo , Easton, Douglas F. , García‐Closas, Montserrat , Kraft, Peter , Hopper, John L. , Pharoah, Paul D.P., Eccles, Diana , Bowtell, David D.L. , Lambrechts, Diether , Vachon, Celine, Turman, Constance , Lush, Michael J. , Arndt, Volker , Benı́tez, Javier , Bonanni, Bernardo , Broeks, Annegien , Chanock, Stephen Jacob , Chin, Suet‐Feung , Couch, Fergus J. , Cox, Angela , Cross, Simon S. , Cybulski, Cezary , Czene, Kamila , Devilee, Peter , Dunning, Alison M. , Eriksson, Mikael , Giles, Graham G. , Gronwald, Jacek , Hall, Per N , Hankinson, Susan E. , Hartikainen, Jaana M. , Hooning, Maartje J. , Kaaks, Rudolf , Kataja, Vesa , Investigators, kConFab/AOCS, Marchand, Loı̈c Le , Mannermaa, Arto, Martens, John W.M. , Milne, Roger L. , Nevanlinna, Heli , Olson, Janet E. , Rahman, Nazneen , Rudolph, Anja , Seibold, Petra , Tsimiklis, Helen , Vachon, Celine M. , Willett, Walter C. , Zheng, Wei , Schmidt, Marjanka K. , Dörk, Thilo , Lambrechts, Diether , Peterlongo, Paolo , Hein, Alexander , Eccles, Diana , Radice, Paolo , Lissowska, Jolanta , Caldas, Carlos , Evans, D Gareth , Southey, Melissa C , Canzian, Federico , Jakubowska, Anna , Lambrechts, Diether , Brenner, Hermann , Li, Jingmei , Muranen, Taru A , García-Closas, Montserrat , Ekici, Arif B , Kraft, Peter , Chenevix-Trench, Georgia , Figueroa, Jonine D , Machiela, Mitchell J , Hüsing, Anika , Bowtell, David D , Pylkäs, Katri , Manoukian, Siranoush , Lubinski, Jan , Bojesen, Stig E , Phillips, Kelly-Anne , Wildiers, Hans , Mclean, Catriona , Lindblom, Annika , Sawyer, Elinor J

Mayo Clinic

International Journal of Epidemiology | June 29, 2017 | Volume: 46 | Issue: 6 | Pages: 1814-1822

10.1093/ije/dyx131 | PMID 29232439 Get It

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Kondrashova, Olga , Nguyen, Minh , Shield‐Artin, Kristy , Tinker, Anna V. , Teng, Nelson N.H., Harrell, Maria I., Barker, Holly E. , Prakash, Rohit , Kass, Elizabeth M. , Sullivan, Meghan R. , Brunette, Gregory J. , Bernstein, Kara A. , Floquet, Anne , Friedländer, Michael , O’Malley, David M. , Oza, Amit M. , Robillard, Liliane, Maloney, Lara , Bowtell, David D.L. , Giordano, Heidi, Wakefield, Matthew J. , Simmons, Andrew D. , Harding, Thomas C., Raponi, Mitch , McNeish, Iain A. , Swisher, Elizabeth M. , Scott, Clare L. , Lin, Kevin K. , Kaufmann, Scott H. , Kuiper, Michael J. , Ho, Gwo‐Yaw , Jasin, Maria , Sullivan, Meghan R. , Coleman, Robert L. , Kichenadasse, Ganessan , Sun, James X. , Lin, Kevin , McNeish, Iain A , Swisher, Elizabeth M , Friedlander, Michael , Wakefield, Matthew J , Scott, Clare L , Bernstein, Kara A , Kondrashova, Olga , Bowtell, David D , Barker, Holly E , O'Malley, David M

Mayo Clinic

Cancer Discovery | June 6, 2017 | Volume: 7 | Issue: 9 | Pages: 984-998

10.1158/2159-8290.cd-17-0419 | PMID 28588062 Get It

Abstract High-grade epithelial ovarian carcinomas containing mutated BRCA1 or BRCA2 (BRCA1/2) homologous recombination (HR) genes are sensitive to platinum-based chemotherapy and PARP inhibitors (PARPi), while restoration of HR function due to secondary mutations in BRCA1/2 has been recognized as an important resistance mechanism. We sequenced core HR pathway genes in 12 pairs of pretreatment and postprogression tumor biopsy samples collected from patients in ARIEL2 Part 1, a phase II study of the PARPi rucaparib as treatment for platinum-sensitive, relapsed ovarian carcinoma. In 6 of 12 pretreatment biopsies, a truncation mutation in BRCA1, RAD51C, or RAD51D was identified. In five of six paired postprogression biopsies, one or more secondary mutations restored the open reading frame. Four distinct secondary mutations and spatial heterogeneity were observed for RAD51C. In vitro complementation assays and a patient-derived xenograft, as well as predictive molecular modeling, confirmed that resistance to rucaparib was associated with secondary mutations. Significance: Analyses of primary and secondary mutations in RAD51C and RAD51D provide evidence for these primary mutations in conferring PARPi sensitivity and secondary mutations as a mechanism of acquired PARPi resistance. PARPi resistance due to secondary mutations underpins the need for early delivery of PARPi therapy and for combination strategies. Cancer Discov; 7(9); 984–98. ©2017 AACR. See related commentary by Domchek, p. 937. See related article by Quigley et al., p. 999. See related article by Goodall et al., p. 1006. This article is highlighted in the In This Issue feature, p. 920
Correction for Evans et al., “Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics To Identify Susceptibility and Resistance to Carbapenems against Acinetobacter spp. in PRIMERS III”
Hujer, Andrea M. , Jiang, Hongyu , Hill, Carol , Hujer, Kristine M., Mediavilla, José R. , Tran, Thuy Tien T., Higgins, Paul G. , Kreiswirth, Barry N. , Patel, Robin , Chen, Liang , Sampath, Rangarajan , Marzan, Christine, Fowler, Vance G. , Chambers, Henry F. , Evans, Scott , Manca, Claudia , Domitrovic, Tatiana , Seifert, Harald , Kreiswirth, Barry N , Jacobs, Michael R. , Chen, Liang , Hall, Thomas A. , Fowler, Vance G. , Bonomo, Robert A. , Patel, Robin , Evans, Scott R

Mayo Clinic

Journal of Clinical Microbiology | May 23, 2017 | Volume: 55 | Issue: 6 | Pages: 1970-1970

10.1128/jcm.00525-17 | PMID 28536161 Get It

Sublethal oligodendrocyte injury: A reversible condition in multiple sclerosis?
Cui, Qiao‐Ling , Khan, Damla, Rone, Malena B., Rao, Vijayaraghava T.S. , Johnson, Radia Marie , Lin, Yun Hsuan , Bilodeau, Philippe‐Antoine , Hall, Jeffery A. , Rodriguez, Moses , Ludwin, Samuel K., Antel, Jack P. , Kennedy, Timothy E. , Bilodeau, Philippe A , Rodriguez, Moses

Mayo Clinic

Annals of Neurology | May 3, 2017 | Volume: 81 | Issue: 6 | Pages: 811-824

10.1002/ana.24944 | PMID 28470695 Get It

ObjectiveDegeneration of oligodendroglial distal processes has been identified as an early event in multiple sclerosis (MS) lesion development. Our objective was to further define the development of the “dying‐back” oligodendrocyte lesion in situ and to model the development and potential reversibility of such responses using dissociated cultures of adult human brain‐derived oligodendrocytes.MethodsIn situ analyses were performed on glutaraldehyde‐fixed thin sections of clinically acute and pathologically active cases of MS. In vitro studies were conducted using adult human brain‐derived oligodendrocytes challenged by metabolic stress conditions (low nutrient/glucose).ResultsIn situ analyses indicated a spectrum of myelin changes in the presence of morphologically intact oligodendrocytes; these included degeneration of the inner cytoplasmic tongue with increasing sizes of intramyelinic bleb formation that could result in radial fractures of the myelin sheath. Macrophages with ingested myelin fragments were identified only once the fragmentation was established. In vitro studies indicated that oligodendrocyte process retraction, which was linked to reduced glycolytic respiratory activity, is reversible until a critical time point. Subsequent cell death was not linked to caspase‐3–dependent programs. Gene expression studies conducted at the latest reversible time point revealed reduced expression of pathways associated with cell process outgrowth and myelination, as well as with metabolic activity.InterpretationOur findings reveal the potential to protect and possibly restore myelin elaborated by existent oligodendrocytes in early and evolving MS lesions, and suggest the necessity of ongoing studies of the mechanisms underlying subsequent adult human oligodendrocyte cell death. Ann Neurol 2017;81:811–824
Medicaid Savings From The New York University Caregiver Intervention for Families with Dementia
Moriarty, James P. , Farseth, Paul, Mittelman, Mary , Long, Kirsten Hall , Foldes, Steven S.

Mayo Clinic

The Gerontologist | May 2, 2017 | Volume: 58 | Issue: 2 | Pages: e97-e106

10.1093/geront/gnx077 | PMID 29106531 Get It

A Diagnostic Marker to Discriminate Childhood Apraxia of Speech From Speech Delay: II. Validity Studies of the Pause Marker
Shriberg, Lawrence D., Fourakis, Marios, Jakielski, Kathy J., Hall, Sheryl D., Karlsson, Heather B., Mabie, Heather L. , McSweeny, Jane L., Tilkens, Christie M., Strand, Edythe A. , Wilson, David L.

Mayo Clinic

Journal of Speech, Language, and Hearing Research | April 7, 2017 | Volume: 60 | Issue: 4 | Pages: No page available

10.1044/2016_jslhr-s-15-0297 | PMID 28384803 Get It

Purpose The purpose of this 2nd article in this supplement is to report validity support findings for the Pause Marker (PM), a proposed single-sign diagnostic marker of childhood apraxia of speech (CAS). Method PM scores and additional perceptual and acoustic measures were obtained from 296 participants in cohorts with idiopathic and neurogenetic CAS, adult-onset apraxia of speech and primary progressive apraxia of speech, and idiopathic speech delay. Results Adjusted for questionable specificity disagreements with a pediatric Mayo Clinic diagnostic standard, the estimated sensitivity and specificity, respectively, of the PM were 86.8% and 100% for the CAS cohort, yielding positive and negative likelihood ratios of 56.45 (95% confidence interval [CI]: [1.15, 2763.31]) and 0.13 (95% CI [0.06, 0.30]). Specificity of the PM for 4 cohorts totaling 205 participants with speech delay was 98.5%. Conclusion These findings are interpreted as providing support for the PM as a near-conclusive diagnostic marker of CAS.
A Diagnostic Marker to Discriminate Childhood Apraxia of Speech From Speech Delay: IV. The Pause Marker Index
Shriberg, Lawrence D., Fourakis, Marios, Jakielski, Kathy J., Hall, Sheryl D., Karlsson, Heather B., Mabie, Heather L. , McSweeny, Jane L., Tilkens, Christie M., Strand, Edythe A. , Wilson, David L.

Mayo Clinic

Journal of Speech, Language, and Hearing Research | April 7, 2017 | Volume: 60 | Issue: 4 | Pages: No page available

10.1044/2016_jslhr-s-16-0149 | PMID 28384662 Get It

Purpose Three previous articles provided rationale, methods, and several forms of validity support for a diagnostic marker of childhood apraxia of speech (CAS), termed the pause marker (PM). Goals of the present article were to assess the validity and stability of the PM Index (PMI) to scale CAS severity. Method PM scores and speech, prosody, and voice precision-stability data were obtained for participants with CAS in idiopathic, neurogenetic, and complex neurodevelopmental disorders; adult-onset apraxia of speech consequent to stroke and primary progressive apraxia; and idiopathic speech delay. Three studies were completed including criterion and concurrent validity studies of the PMI and a temporal stability study of the PMI using retrospective case studies. Results PM scores were significantly correlated with other signs of CAS precision and stability. The best fit of the distribution of PM scores to index CAS severity was obtained by dividing scores into 4 ordinal severity classifications: mild, mild-moderate, moderate-severe, and severe. Severity findings for the 4 classifications and retrospective longitudinal findings from 8 participants with CAS supported the validity and stability of the PMI. Conclusion Findings support research and clinical use of the PMI to scale the severity of CAS.